SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
This article was originally published in The Tan Sheet
Executive Summary
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm
You may also be interested in...
In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC
Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.
In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC
Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.
NACDS New Products In Brief
Reckitt doubles down with Mucinex